Alembic Pharma Receives FDA Approval for Generic Ophthalmic Solution, Estimated Market Size at $61 Million
ByAinvest
Thursday, Dec 18, 2025 11:29 pm ET1min read
Alembic Pharmaceuticals has received FDA approval for its generic Travoprost Ophthalmic Solution, equivalent to Sandoz's Travatan Z. The solution is used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product has an estimated market size of $61 million for the twelve months ending September 2025.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet